This phase I study is seeking to determine the best dose level, safety and effectiveness of a new cancer treatment (AMT-151) in people with certain advanced solid cancers.
This trial is treating patients with advanced serous, endometrioid, clear-cell, or mucinous epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; serous, endometrioid, or clear-cell endometrial cancer; adenocarcinoma of the lung; triple-negative breast cancer; pancreatic ductal adenocarcinoma; and malignant pleural mesothelioma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics Inc.
Eligible participants will receive AMT-151 intravenously (via IV).
Recruiting Hospitals Read More